BCMU
LSTA icon

BlueCrest Capital Management (UK)’s Lisata Therapeutics LSTA Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-109
Closed -$115K – 665
2014
Q1 		$115K Buy
+109
New +$118K 0.01% 485

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

BlueCrest Capital Management (UK)'s LSTA Position: Q2 2014 in Review

BlueCrest Capital Management (UK) sold out of Lisata Therapeutics (LSTA) in Q2 2014, closing a stake of 109 shares — an estimated $115K sold.

BlueCrest Capital Management (UK) first reported a position in LSTA in Q1 2014 and held it in 1 quarter. The position peaked at $115K in Q1 2014. 58 funds tracked by Wall St. Rank hold LSTA as of Q2 2014.

  • BlueCrest Capital Management (UK) reported no remaining Lisata Therapeutics position as of Q2 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 109 Lisata Therapeutics shares in Q2 2014, an estimated $115K.
  • BlueCrest Capital Management (UK) first reported a position in Lisata Therapeutics in Q1 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Lisata Therapeutics position peaked at $115K in Q1 2014.
  • 58 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q2 2014, filed 15 Aug 2014.